• 1
    Teske E, van Straten G, van Noort R and Rutteman GR. Chemotherapy with cyclophosphamide, vincristine, and prednisolone (COP) in cats with malignant lymphoma: New results with an old protocol. Journal of Veterinary Internal Medicine 2002; 16: 179186.
  • 2
    Louwerens M, London CA, Pedersen NC and Lyons LA. Feline lymphoma in the post–feline leukemia virus era. Journal of Veterinary Internal Medicine 2005; 19: 329335.
  • 3
    Hayes A. Feline lymphoma 1. Principles of diagnosis and management. In Practice 2006; 28: 516524.
  • 4
    Malik R, Gabor LJ and Canfield PJ. Lymphoma in Australian cats-lessons for Europe? Journal of Feline Medicine and Surgery 2003; 5: 147150.
  • 5
    Ettinger SN. Principles of treatment for feline lymphoma. Clinical Techniques in Small Animal Practice 2003; 18: 98102.
  • 6
    Vail DM, Moore AS, Ogilvie GK and Volk LM. Feline lymphoma (145 cases): proliferation indices, cluster of differentiation 3 immunoreactivity, and their association with prognosis in 90 cats. Journal of Veterinary Internal Medicine 1998; 12: 349354.
  • 7
    Simon D, Eberle N, Laacke-Singer L and Nolte I. Combination chemotherapy in feline lymphoma: treatment outcome, tolerability, and duration in 23 cats. Journal of Veterinary Internal Medicine 2008; 22: 394400.
  • 8
    Cotter SM. Treatment of lymphoma and leukemia with cyclophosphamide, vincristine and prednisolone: II. Treatment of cats. Journal of the American Animal Hospital Association 1983; 19: 166172.
  • 9
    Los G, Mutsaers PHA, van der Vijgh WJF, Baldew GS, de Graaf PW and MeVie JG. Direct diffusion of cfV diamminedichloroplatinum (II) in intraperitoneal rat tumors after intraperitonal chemotherapy: a comparison with systemic chemotherapy. Cancer Research 1989; 49: 33803384.
  • 10
    Markman M. Intraperitoneal chemotherapy. Critical Reviews in Oncology: Hematology 1999; 31: 239246.
  • 11
    VCOG. Veterinary Co-Operative Oncology Group-common terminology criteria for adverse events (VCOG-CTCAE) following chemotherapy or biological antineoplastic therapy in dogs and cats. Veterinary Comparative Oncology 2004; 2: 194213.
  • 12
    Markman M. Intraperitoneal antineoplastic drug delivery: rationale and results. The Lancelet Oncology 2003; 4: 277283.
  • 13
    Markman M. Intraperitoneal chemotherapy. In: Perry MC (ed). The chemotherapy source book. 4th ed. Philadelphia, PA, Lippincott Wilkins & Williams. 2007:7577.
  • 14
    Miyagi Y, Fujiwara K, Kigawa J, Itamochi H, Nagao S, Aotani E, Terakawa N, Kohno I and Sankai Gynecology Study Group (SGSG). Intraperitoneal carboplatin infusion may be a pharmacologically more reasonable route than intravenous administration as a systemic chemotherapy. A comparative pharmacokinetic analysis of platinum using a new mathematical model after intraperitoneal vs. intravenous infusion of carboplatin – a Sankai Gynecology Study Group (SGSG) study. Gynecologic Oncology 2005; 99: 591596.
  • 15
    Gabor LJ, Jackson ML, Trask B, Malik R and Canfield PJ. Feline leukemia virus status of Australian cats with lymphosarcoma. Australian Veterinary Journal 2001; 79: 476481.
  • 16
    Milner RJ, Peyton J, Cooke K, Fox LE, Gallagher A, Gordon P and Hester J. Response rates and survival times for cats with lymphoma treated with the University of Wisconsin-Madison chemotherapy protocol: 38 cases (1996–2003). Journal of the American Veterinary Medical Association 2005; 7: 11181122.
  • 17
    Court EA, Watson AD and Peaston AE. Retrospective study of 60 cases of feline lymphosarcoma. Australian Veterinary Journal 1997; 6: 424427.
  • 18
    Mooney SC, Hayes AA, MacEwen EG, Matus RE, Geary A and Shurgot BA. Treatment and prognostic factors in lymphoma in cats: 103 cases (1977–1981). Journal of the American Veterinary Medical Association 1989; 194: 349354.
  • 19
    Stützer B, Simon K, Lutz H, Majzoub M, Hermanns W, Hirschberger J, Sauter-Louis C and Hartmann K. Incidence of persistent viraemia and latent feline leukaemia virus infection in cats with lymphoma. Journal of Feline Medicine and Surgery 2011; 13: 8187.
  • 20
    Moore AS, Cotter SM, Frimberger AE, Wood CA, Rand WM and L'Heureux DA. A comparison of doxorubicin and COP for maintenance of remission in cats with lymphoma. Journal of Veterinary Internal Medicine 1996; 10: 372375.
  • 21
    Kristal O, Lana SE, Ogilvie GK, Rand WM, Cotter SM and Moore AS. Single agent chemotherapy with doxorubicin for feline lymphoma: a retrospective study of 19 cases (1994–1997). Journal of Veterinary Internal Medicine 2001; 15: 125130.
  • 22
    Patterson-Kane JC, Perrins Kugler B and Francis K. The possible prognostic significance of immunophenotype in feline alimentary lymphoma: a pilot study. Journal of Comparative Pathology 2004; 130: 220222.
  • 23
    Gabor LJ, Canfield PJ and Malik R. Immunophenotypic and histological characterization of 109 cases of feline lymphosarcoma. Australian Veterinary Journal 1999; 77: 436441.
  • 24
    Piek CJ, Rutteman GR and Teske E. Evaluation of the results of a L-asparaginase-based continuous chemotherapy protocol versus a short doxorubicin-based induction chemotherapy protocol in dogs with malignant lymphoma. Veterinary Quarterly 1999; 21: 4449.
  • 25
    Tzannes S, Hammond MF, Murphy S, Sparkes A and Blackwood L. Owners ‘perception of their cats’ quality of life during COP chemotherapy for lymphoma. Journal of Feline Medicine and Surgery 2008; 10: 7381.
  • 26
    Brønden LB, Rutteman GR, Flagstad A and Teske E. Study of dog and cat owners' perceptions of medical treatment for cancer. Veterinary Record 2003; 152: 7780.
  • 27
    ECVIM-CA. Preventing Occupational and Environmental Exposure to Cytotoxic Drugs in Veterinary Medicine, 2nd edn., 2007. [accessed 11 March 2012].